Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 7, 2014, Pages 907-914

  Carrascosa, J M ^a   Vilavella, M ^a   Garcia Doval, I ^b   Carretero, G ^c   Vanaclocha, F ^d   Dauden E ^e   Gomez Garcia F J ^f   Herrera Ceballos, E ^g   De La Cueva Dobao, P ^h   Belinchon I ⁱ   Sanchez Carazo J L ^j   Alsina, M ^k   Lopez Estebaranz J L ^l   Ferran M ^m   Peral, F ⁿ   Torrado, R ^c   Rivera, R ^d   Jimenez Puya R ^f   Mendiola, M V ^g   Ferrandiz C ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Research Unit   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

ARTICLE; BIOLOGICAL THERAPY; BODY MASS; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PSORIASIS; REMISSION; RISK FACTOR; SIDE EFFECT; SPAIN; SURVIVAL RATE; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; MULTIVARIATE ANALYSIS; OVERWEIGHT; PREVALENCE; PROSPECTIVE STUDY; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

BIOLOGICAL PRODUCTS; BODY MASS INDEX; COMORBIDITY; HUMANS; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; PREVALENCE; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84905028303     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12208     Document Type: Article

References (24)

1. Ferrándiz C, Bordas X, García-Patos V, et al,. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15: 20-23.
2. Sterry W, Strober BE, Menter A,. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655.
3. Naldi L, Chatenoud L, Linder D, et al,. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
4. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization [WWW document] 1995. URL: http://whqlibdoc.who.int/trs/WHO TRS 854.pdf (last accessed: January 2013).
5. Ronti T, Lupattelli G, Mannarino E,. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-365.
6. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses Health Study II. Arch Intern Med 2007; 167: 1670-1675.
7. Ferrándiz C, García A, Blasco AJ, et al,. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 768-777.
8. Rivera R, García-Doval I, Carretero G, et al,. miembros del grupo BIOBADADERM. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biological Drugs in Dermatology: first report. Actas Dermosifiliogr 2011; 102: 132-141.
9. National Health Survey (Encuesta nacional de salud). Instituto Nacional de Estadística URL: http://www.ine.es/jaxi/menu.do?type=pcaxis&path= %2Ft15%2Fp419&file=inebase&L=0 (last accessed: January 2013).
10. Aranceta J, Pérez Rodrigo C, Foz Sala M, et al. Grupo Colaborativo para el estudio DORICA fase 2. Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study. Med Clin (Barc) 2004; 123: 686-691.
11. Lindegård B,. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304.
12. Neimann AL, Shin DB, Wang X, et al,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
13. Armstrong AW, Harskamp CT, Armstrong EJ,. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012 Dec; 3 (2): e54. doi: 10.1038/nutd.2012.26.
14. Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-1011.
15. Johnston A, Arnadottir S, Gudjonsson JE, et al,. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350.
16. Gerdes S, Rostami-Yazdi M, Mrowietz U,. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87.
17. Hayes J, Koo J,. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-180.
18. Gniadecki R, Kragballe K, Dam TN, et al,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
19. Naldi L, Addis A, Chimenti S, et al,. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-373.
20. Zhu Y, Hu C, Lu M, et al,. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-175.
21. Romaní J, Caixàs A, Carrascosa JM, et al,. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol 2012; 166: 1237-1244.
22. Loef M, Walach H,. The combined effects of healthy lifestyle behaviors on all cause mortality: A systematic review and meta-analysis. Prev Med 2012; 55: 163-170.
23. Puig L, Carrascosa JM,. Daudén E et al Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr 2009; 100: 386-413.
24. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and non-biologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.